BACKGROUND: Hypericin is a known photodynamic agent that has been demonstrated to induce apoptosis in normal and malignant B and T lymphocytes, and has potential to treat benign and malignant disorders of the skin, including psoriasis and cutaneous T-cell lymphoma. OBJECTIVE: We wished to test whether topical hypericin was an effective, safe, and well-tolerated therapy for patch or plaque phase mycosis fungoides and for plaque psoriasis. METHODS: We conducted a phase II placebo-controlled clinical study in patients who had either patch or plaque phase mycosis fungoides or plaque type psoriasis vulgaris. Representative lesions were treated twice weekly for 6 weeks with topically applied hypericin or placebo followed 24 hours later by exposure to visible light at 8 to 20 J/cm(2). RESULTS: After 6 weeks of twice-weekly therapy, several concentrations of hypericin resulted in the significant improvement of treated skin lesions among the majority of patients with cutaneous T-cell lymphoma and psoriasis whereas the placebo vehicle was ineffective. LIMITATIONS: The clinical trial involved a small number of patients. CONCLUSIONS: Overall, the data from this study support the conclusion that topical hypericin/visible light photodynamic therapy is an effective and well-tolerated alternative to standard psoralen plus ultraviolet A treatment of these disorders.
RCT Entities:
BACKGROUND:Hypericin is a known photodynamic agent that has been demonstrated to induce apoptosis in normal and malignant B and T lymphocytes, and has potential to treat benign and malignant disorders of the skin, including psoriasis and cutaneous T-cell lymphoma. OBJECTIVE: We wished to test whether topical hypericin was an effective, safe, and well-tolerated therapy for patch or plaque phase mycosis fungoides and for plaque psoriasis. METHODS: We conducted a phase II placebo-controlled clinical study in patients who had either patch or plaque phase mycosis fungoides or plaque type psoriasis vulgaris. Representative lesions were treated twice weekly for 6 weeks with topically applied hypericin or placebo followed 24 hours later by exposure to visible light at 8 to 20 J/cm(2). RESULTS: After 6 weeks of twice-weekly therapy, several concentrations of hypericin resulted in the significant improvement of treated skin lesions among the majority of patients with cutaneous T-cell lymphoma and psoriasis whereas the placebo vehicle was ineffective. LIMITATIONS: The clinical trial involved a small number of patients. CONCLUSIONS: Overall, the data from this study support the conclusion that topical hypericin/visible light photodynamic therapy is an effective and well-tolerated alternative to standard psoralen plus ultraviolet A treatment of these disorders.
Authors: Manuel Pablo Paz-Cristobal; Yolanda Gilaberte; Carmen Alejandre; Julián Pardo; M José Revillo; Antonio Rezusta Journal: Mycopathologia Date: 2014-08-17 Impact factor: 2.574
Authors: Janet Y Li; Steven Horwitz; Alison Moskowitz; Patricia L Myskowski; Melissa Pulitzer; Christiane Querfeld Journal: Cancer Manag Res Date: 2012-03-12 Impact factor: 3.989
Authors: Abhishek D Garg; Lorenzo Galluzzi; Lionel Apetoh; Thais Baert; Raymond B Birge; José Manuel Bravo-San Pedro; Karine Breckpot; David Brough; Ricardo Chaurio; Mara Cirone; An Coosemans; Pierre G Coulie; Dirk De Ruysscher; Luciana Dini; Peter de Witte; Aleksandra M Dudek-Peric; Alberto Faggioni; Jitka Fucikova; Udo S Gaipl; Jakub Golab; Marie-Lise Gougeon; Michael R Hamblin; Akseli Hemminki; Martin Herrmann; James W Hodge; Oliver Kepp; Guido Kroemer; Dmitri V Krysko; Walter G Land; Frank Madeo; Angelo A Manfredi; Stephen R Mattarollo; Christian Maueroder; Nicolò Merendino; Gabriele Multhoff; Thomas Pabst; Jean-Ehrland Ricci; Chiara Riganti; Erminia Romano; Nicole Rufo; Mark J Smyth; Jürgen Sonnemann; Radek Spisek; John Stagg; Erika Vacchelli; Peter Vandenabeele; Lien Vandenberk; Benoit J Van den Eynde; Stefaan Van Gool; Francesca Velotti; Laurence Zitvogel; Patrizia Agostinis Journal: Front Immunol Date: 2015-11-20 Impact factor: 7.561